Antimicrobial Agents and Chemotherapy 2009-03-01

Association between antimicrobial consumption and resistance in Escherichia coli.

Miika Bergman, Solja T Nyberg, Pentti Huovinen, Pirkko Paakkari, Antti J Hakanen

Index: Antimicrob. Agents Chemother. 53(3) , 912-7, (2009)

Full Text: HTML

Abstract

During a 9-year study period from 1997 through 2005, the association between antimicrobial resistance rates in Escherichia coli and outpatient antimicrobial consumption was investigated in 20 hospital districts in Finland. A total of 754,293 E. coli isolates, mainly from urine samples, were tested for antimicrobial resistance in 26 clinical microbiology laboratories. The following antimicrobials were studied: ampicillin, amoxicillin-clavulanate, cephalosporins, fluoroquinolones, trimethoprim, trimethoprim-sulfamethoxazole, pivmecillinam, and nitrofurantoin. We applied a protocol used in earlier studies in which the level of antimicrobial consumption over 1 year was compared with the level of resistance in the next year. Statistically significant associations were found for nitrofurantoin use versus nitrofurantoin resistance (P < 0.0001), cephalosporin use versus nitrofurantoin resistance (P = 0.0293), amoxicillin use versus fluoroquinolone resistance (P = 0.0031), and fluoroquinolone use versus ampicillin resistance (P = 0.0046). Interestingly, we found only a few associations between resistance and antimicrobial consumption. The majority of the associations studied were not significant, including the association between fluoroquinolone use and fluoroquinolone resistance.


Related Compounds

Related Articles:

Use of antibiotics in nursing homes--surveillance with different methods.

2013-10-15

[Tidsskr. Nor. Laegeforen. 133(19) , 2052-6, (2013)]

New media for the semiselective isolation and enumeration of Xanthomonas campestris pv. mangiferaeindicae, the causal agent of mango bacterial black spot.

2005-01-01

[J. Appl. Microbiol. 99(4) , 803-15, (2005)]

Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

2010-09-01

[Antimicrob. Agents Chemother. 54 , 4006-8, (2010)]

Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project.

2007-03-01

[Scand. J. Prim. Health Care 25(1) , 49-57, (2007)]

The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study.

2004-01-01

[Scand. J. Infect. Dis. 36(4) , 296-301, (2004)]

More Articles...